Plant Name: Aloe vera
Taxonomic Information:
Plant ID: NPO11578
Plant Latin Name: Aloe vera
Taxonomy Genus: Aloe
Taxonomy Family: Xanthorrhoeaceae
Plant External Links:
NCBI TaxonomyDB:
34199
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Brazil; Madagascar; Italy; Swaziland; Argentina; Bolivia; Venezuela; Nigeria; Saudi Arabia; Zimbabwe; Jordan; Thailand; Philippines; Indonesia; United States; Vietnam; Switzerland; Angola; Mexico; Tunisia; South Africa; India; Malaysia; China; Kenya; South KoreaTraditional Medicine System:
Sowa-Rigpa; Indian Folk; Unani; Siddha; Ayurveda; TCMMedicinal Functions:
Cancer; Emmenagogue; Emollient; Laxative; Miscellany; Purgative; Skin; Stimulant; Stomachic; Tonic; Vermifuge; Vulnerary
Geographical Distribution:
Brazil; Madagascar; Italy; Swaziland; Argentina; Bolivia; Venezuela; Nigeria; Saudi Arabia; Zimbabwe; Jordan; Thailand; Philippines; Indonesia; United States; Vietnam; Switzerland; Angola; Mexico; Tunisia; South Africa; India; Malaysia; China; Kenya; South Korea
Example Image
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| FFAR4; ADRA2B; FFAR1; | |
| TSHR; NPSR1; | |
| BLM; ALPL; TDP1; ALOX12; HSD17B2; HSD17B10; ALOX15; NOX4; ALDH1A1; HSD17B1; GSTK1; POLB; | |
| ACHE; | |
| GABRR1; | |
| MET; FLT3; CDK1; MAPK1; PIM1; AXL; KDR; IGF1R; AURKB; CSNK2A1; | |
| CA2; CA12; CA14; CA7; | |
| PPARA; | |
| ESR2; | |
| TYR; | |
| MMP9; MMP1; MMP2; | |
| AHR; HIF1A; TP53; NFKB1; | |
| KMT2A; | |
| FABP3; FABP5; FABP4; LMNA; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
| Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
| Enzyme_unclassified | GSTK1 | Glutathione S-transferase kappa 1 | Q9Y2Q3 | CHEMBL4491 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| GABA-A receptor | GABRR1 | GABA receptor rho-1 subunit | P24046 | CHEMBL3561 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Plant homeodomain | KMT2A | Histone-lysine N-methyltransferase MLL | Q03164 | CHEMBL1293299 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
| Small molecule receptor (family A GPCR) | ADRA2B | Alpha-2b adrenergic receptor | P18089 | CHEMBL1942 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 3.364E-09 | 4.309E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.313E-08 | 1.133E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 8.443E-08 | 4.378E-05 | CA12, CA14, CA2, CA7 |
| BP | GO:0050896; response to stimulus | GO:0033993; response to lipid | 1.069E-07 | 5.291E-05 | ALPL, AXL, CA2, CSNK2A1, CYP1A1, CYP1A2, FABP3, FFAR1, FLT3, HSD17B2, NFKB1, TP53, TYR |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.655E-07 | 1.560E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.869E-07 | 1.620E-04 | ALOX12, ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.384E-07 | 2.057E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.058E-06 | 3.273E-04 | FABP3, FABP4, FABP5, FFAR4 |
| BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 1.115E-06 | 3.371E-04 | ALOX12, CDK1, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MAPK1, MMP2, MMP9, PIM1, THPO, TSHR |
| MF | GO:0005488; binding | GO:0020037; heme binding | 1.863E-06 | 4.947E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9, NOX4 |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.144E-06 | 5.559E-04 | AHR, CSNK2A1, HIF1A, KDR |
| BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 6.467E-06 | 1.292E-03 | CYP19A1, HSD17B1, HSD17B2 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 7.291E-06 | 1.417E-03 | ALPL, BLM, CYP1A1, CYP1B1, FLT3, MAPK1, NFKB1, NOX4 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 7.889E-06 | 1.468E-03 | CA12, CA14, CA2, CA7 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 8.255E-06 | 1.486E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 8.255E-06 | 1.486E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0001666; response to hypoxia | 9.515E-06 | 1.670E-03 | CYP1A1, HIF1A, LMNA, MMP2, NOX4, PPARA, TP53 |
| BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 9.589E-06 | 1.670E-03 | ALOX15, AURKB, HIF1A, KDR, KMT2A, MAPK1, MET, MMP9, NOX4, TP53 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 9.878E-06 | 1.707E-03 | ACHE, BLM, CSNK2A1, ESR2, FLT3, IGF1R, KDR, KMT2A, MAPK1, MET, MMP9, NFKB1, SMN1, SMN2, TP53, TYR |
| BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.287E-05 | 2.124E-03 | ACHE, ALOX15, CDK1, CYP1A1, PPARA, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 1.716E-05 | 2.688E-03 | BLM, IGF1R, MAPK1, MMP2, NFKB1, NOX4, TP53, TSHR |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.743E-05 | 2.711E-03 | ALPL, CA2, CSNK2A1, CYP1A2, FABP3, FFAR4, FLT3, NFKB1, PPARA, TSHR |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.803E-05 | 2.785E-03 | BLM, CA12, CA2, CA7, ESR2, KMT2A, MMP1, MMP2, MMP9, PPARA, TP53 |
| BP | GO:0065007; biological regulation | GO:0048872; homeostasis of number of cells | 2.143E-05 | 3.107E-03 | AXL, FLT3, HIF1A, KMT2A, POLB |
| BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.153E-05 | 3.107E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
| BP | GO:0032501; multicellular organismal process | GO:0035162; embryonic hemopoiesis | 2.164E-05 | 3.107E-03 | HIF1A, KDR, KMT2A |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.472E-05 | 3.385E-03 | CA2, CA7 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 2.472E-05 | 3.385E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 2.472E-05 | 3.385E-03 | ALOX12, ALOX15 |
| BP | GO:0050896; response to stimulus | GO:0009314; response to radiation | 2.755E-05 | 3.749E-03 | AURKB, BLM, HIF1A, KMT2A, NOX4, POLB, TP53, TYR |
| MF | GO:0060089; molecular transducer activity | GO:0038023; signaling receptor activity | 2.778E-05 | 3.757E-03 | ADRA2B, AHR, AXL, ESR2, FFAR1, FFAR4, FLT3, GABRR1, IGF1R, KDR, MET, NPSR1, PPARA, TSHR |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.958E-05 | 3.952E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0031328; positive regulation of cellular biosynthetic process | 3.032E-05 | 4.020E-03 | AHR, AURKB, BLM, CDK1, ESR2, FABP3, HIF1A, IGF1R, KMT2A, MAPK1, MET, NFKB1, NOX4, PPARA, TP53, TSHR |
| BP | GO:0009987; cellular process | GO:0030154; cell differentiation | 3.598E-05 | 4.641E-03 | ALPL, AXL, CDK1, CYP1A1, FABP4, FFAR4, FLT3, GSTK1, HIF1A, KDR, MAPK1, MMP2, MMP9, NOX4, THPO, TP53 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.923E-05 | 4.966E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.935E-05 | 6.003E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.935E-05 | 6.003E-03 | CYP1A2, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 5.074E-05 | 6.104E-03 | FABP3, FABP4, FABP5 |
| BP | GO:0032502; developmental process | GO:0007568; aging | 5.401E-05 | 6.462E-03 | AURKB, CDK1, CYP1A1, NOX4, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0010557; positive regulation of macromolecule biosynthetic process | 5.512E-05 | 6.559E-03 | AHR, AURKB, BLM, CDK1, ESR2, HIF1A, IGF1R, KDR, KMT2A, MAPK1, MET, NFKB1, NOX4, PPARA, TP53 |
| BP | GO:0050896; response to stimulus | GO:1901652; response to peptide | 6.415E-05 | 7.523E-03 | FABP3, FFAR4, IGF1R, NFKB1, PPARA, TP53, TSHR |
| BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 6.960E-05 | 7.976E-03 | AXL, CDK1, CSNK2A1, FLT3 |
| BP | GO:0009987; cellular process | GO:0071345; cellular response to cytokine stimulus | 7.140E-05 | 8.100E-03 | ALOX15, AXL, FABP4, FLT3, HIF1A, MAPK1, NFKB1 |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 8.209E-05 | 8.938E-03 | ALOX12, ALOX15 |
| BP | GO:0051179; localization | GO:0051050; positive regulation of transport | 8.680E-05 | 9.357E-03 | ACHE, AXL, CA2, CDK1, CYP19A1, FFAR1, HIF1A, KMT2A, MAPK1, NPSR1, TP53 |
| BP | GO:0008152; metabolic process | GO:0032963; collagen metabolic process | 8.929E-05 | 9.565E-03 | HIF1A, MMP1, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0007169; transmembrane receptor protein tyrosine kinase signaling pathway | 8.961E-05 | 9.565E-03 | AXL, FLT3, IGF1R, KDR, MAPK1, MET, MMP2, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0033273; response to vitamin | 9.367E-05 | 9.901E-03 | ALPL, CYP1A1, TP53, TYR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.285E-09 | 8.668E-07 | HSD17B1, HSD17B2, CYP1A1, CYP1B1, CYP19A1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 9.181E-08 | 3.659E-06 | MMP2, KDR, MAPK1, TP53, HIF1A, MMP9, MET, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.323E-08 | 1.085E-06 | HSD17B1, CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP19A1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 1.339E-07 | 3.659E-06 | FLT3, MMP1, MMP2, MAPK1, HIF1A, MET, TP53, MMP9, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 9.948E-08 | 3.659E-06 | MMP1, MMP2, MAPK1, MMP9, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 6.804E-07 | 1.594E-05 | KMT2A, FLT3, TP53, MMP9, MET, NFKB1, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.213E-06 | 2.487E-05 | FLT3, MAPK1, TP53, MET, HIF1A |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.863E-06 | 3.055E-05 | CYP2C9, GSTK1, CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 1.406E-06 | 2.561E-05 | FABP3, FABP4, FABP5, MMP1, PPARA |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.846E-05 | 2.460E-04 | PIM1, CYP1B1, MAPK1, TP53, MMP9, MET, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.320E-06 | 4.950E-05 | CYP2C9, GSTK1, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.277E-07 | 3.659E-06 | CA12, CA2, CA7, CA14 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.950E-05 | 2.460E-04 | FLT3, PIM1, MAPK1, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 4.658E-05 | 5.093E-04 | MAPK1, TP53, MET, IGF1R |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 3.287E-05 | 3.850E-04 | CYP2C9, CYP1A2, ALDH1A1, CYP1A1 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.329E-04 | 1.148E-03 | CYP2C9, HSD17B1, HSD17B2, CYP1A2, ALOX15, ALDH1A1, CYP1A1, ALPL, ALOX12, TYR, CYP19A1, HSD17B10 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 5.482E-05 | 5.619E-04 | CSNK2A1, MAPK1, MET, IGF1R |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.128E-04 | 1.027E-03 | MAPK1, TP53, NFKB1, IGF1R |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.839E-04 | 1.414E-03 | MMP2, PIM1, MAPK1, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.703E-04 | 1.396E-03 | MMP2, MAPK1, MMP9, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 2.692E-04 | 1.794E-03 | POLB, CDK1, MAPK1, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 3.723E-04 | 2.349E-03 | KDR, MAPK1, TP53, MET, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.984E-04 | 1.414E-03 | MAPK1, HIF1A, NFKB1, IGF1R |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 4.298E-04 | 2.611E-03 | KDR, MAPK1, MET, NFKB1, IGF1R |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.735E-04 | 1.794E-03 | CYP2C9, ALOX15, MAPK1, ALOX12 |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 6.370E-04 | 3.602E-03 | LMNA, MAPK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 5.252E-04 | 3.076E-03 | MAPK1, PPARA, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 7.455E-04 | 3.944E-03 | MAPK1, TP53, MMP9, NFKB1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.909E-04 | 1.414E-03 | CYP1A2, CYP1A1, CYP1B1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 8.031E-04 | 4.050E-03 | MAPK1, TP53, IGF1R |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 7.215E-05 | 6.961E-04 | CYP2C9, CYP1A2, ALOX15 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 8.397E-04 | 4.050E-03 | MAPK1, TP53, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 6.995E-04 | 3.824E-03 | CYP2C9, ALOX15, ALOX12 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 2.332E-03 | 9.561E-03 | MAPK1, PPARA, NFKB1, TSHR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05168 | Herpes simplex infection | 1.789E-03 | 7.720E-03 | CSNK2A1, CDK1, TP53, NFKB1 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 2.462E-03 | 9.612E-03 | CSNK2A1, CDK1, TP53, NFKB1 |
| 09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 2.462E-03 | 9.612E-03 | KDR, MAPK1, MET, IGF1R |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.081E-03 | 4.927E-03 | MAPK1, NFKB1, ESR2 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 8.397E-04 | 4.050E-03 | MAPK1, MET, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 1.126E-03 | 4.989E-03 | MAPK1, TP53, NFKB1 |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 2.327E-03 | 9.561E-03 | TP53, NFKB1, IGF1R |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 9.557E-04 | 4.478E-03 | CYP2C9, GSTK1, CYP1A2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 2.620E-03 | 9.993E-03 | CDK1, MAPK1, IGF1R |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
| NA: NA | Edema | NA | CA2; |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MMP1; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; MMP9; TP53; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
| NA: NA | HIV infections | NA | AHR; |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MMP1; TYR; |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
| C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; TP53; |
| C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; NFKB1; FLT3; ACHE; HIF1A; MMP9; MAPK1; TP53; MMP2; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ADRA2B; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MMP9; MAPK1; TP53; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; FFAR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP2; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
| C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; MMP2; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; MMP2; |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
| C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; MMP2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA2; |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADRA2B; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | MMP1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9; |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioma | C71 | KDR; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
